52. Mixed connective tissue disease Disease details / Clinical trials / Drug dev / DR info

Clinical trials : 9 /  Drugs : 8 - (DrugBank : 4) / Drug target gene : 1 - Drug target pathway : 1

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
Cyclophosphamide
   Royal Brompton & Harefield NHS Foundation Trust
      2014   Phase 2/Phase 3   NCT01862926   United Kingdom
Cyclophosphamide injection 1G
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom
Mabthera
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom
MHV370
   Novartis Farmacéutica, S.A.
      2021   Phase 2   EUCTR2020-004937-19-ES   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom
   Novartis Pharma AG
      2021   Phase 2   EUCTR2020-004937-19-HU   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom
      2021   Phase 2   EUCTR2020-004937-19-DE   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04988087   China;Germany;Hungary;Poland;Spain;Switzerland;Taiwan;United Kingdom
Rituximab
   Royal Brompton & Harefield NHS Foundation Trust
      2014   Phase 2/Phase 3   NCT01862926   United Kingdom
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom
   Yokohama City University Hospital Department of Pediatrics
      2015   -   JPRN-UMIN000018376   Japan
Sodium thiosulfate
   Robyn T. Domsic, MD, MPH
      2025   Phase 2   NCT06672822   United States
STS
   Robyn T. Domsic, MD, MPH
      2025   Phase 2   NCT06672822   United States
Yellow fever vaccine
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil